Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Recommendation of “Buy” by Brokerages

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has earned a consensus rating of “Buy” from the nine brokerages that are presently covering the company, MarketBeat reports. Nine research analysts have rated the stock with a buy rating. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $61.5714.

Several research analysts have weighed in on the stock. Stifel Nicolaus upped their price objective on shares of Dianthus Therapeutics from $52.00 to $65.00 and gave the company a “buy” rating in a research note on Friday, September 12th. Guggenheim upped their price objective on shares of Dianthus Therapeutics from $92.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday, September 9th. Raymond James Financial restated an “outperform” rating and set a $63.00 price target (up previously from $56.00) on shares of Dianthus Therapeutics in a research note on Tuesday, September 9th. William Blair assumed coverage on shares of Dianthus Therapeutics in a research note on Wednesday, July 2nd. They set an “outperform” rating on the stock. Finally, Wedbush increased their price target on shares of Dianthus Therapeutics from $42.00 to $44.00 and gave the stock an “outperform” rating in a research note on Friday, September 12th.

Dianthus Therapeutics Stock Performance

Shares of NASDAQ:DNTH opened at $36.93 on Friday. The company has a market cap of $1.19 billion, a PE ratio of -11.36 and a beta of 1.58. Dianthus Therapeutics has a 52 week low of $13.36 and a 52 week high of $40.16. The firm has a 50 day simple moving average of $27.93 and a 200 day simple moving average of $22.06.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.02). The firm had revenue of $0.19 million during the quarter, compared to analysts’ expectations of $0.87 million. Dianthus Therapeutics had a negative net margin of 2,364.56% and a negative return on equity of 34.72%. On average, equities analysts predict that Dianthus Therapeutics will post -2.61 earnings per share for the current year.

Insider Activity

In related news, CFO Ryan Savitz sold 20,000 shares of the company’s stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $35.00, for a total transaction of $700,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 8.15% of the company’s stock.

Institutional Trading of Dianthus Therapeutics

A number of hedge funds have recently bought and sold shares of DNTH. BNP Paribas Financial Markets bought a new stake in Dianthus Therapeutics in the 4th quarter valued at $59,000. Millennium Management LLC lifted its holdings in shares of Dianthus Therapeutics by 160.2% during the 4th quarter. Millennium Management LLC now owns 90,436 shares of the company’s stock worth $1,972,000 after acquiring an additional 55,682 shares during the period. Wellington Management Group LLP lifted its holdings in shares of Dianthus Therapeutics by 12.2% during the 4th quarter. Wellington Management Group LLP now owns 60,337 shares of the company’s stock worth $1,315,000 after acquiring an additional 6,552 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Dianthus Therapeutics by 3,030.6% during the 1st quarter. GAMMA Investing LLC now owns 3,882 shares of the company’s stock worth $70,000 after acquiring an additional 3,758 shares during the period. Finally, Moody Aldrich Partners LLC bought a new position in shares of Dianthus Therapeutics during the 1st quarter worth about $1,349,000. 47.53% of the stock is owned by institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.